To investigate the effects of low-level laser therapy (LLLT) as a new nonpharmaceutical approach to improve cognitive symptoms in patients with dementia.
Background:
Routine pharmacological treatment of dementia patients is inefficient and has considerable adverse effects. Recent attempts to develop nonpharmaceutical approaches are considered favorable for patients with dementia.
Methods:
Thirty-two patients with dementia were randomly divided into the same population of LLLT and sham groups. The LLLT group underwent transcranial LLLT, and the sham group received the same protocol with a zero-intensity laser. All patients in the two groups were evaluated using the minimental state examination (MMSE) and clinical dementia rating (CDR) tests at the time of admission as baseline at 2 and 6 weeks postintervention.
Results:
The rate of change of MMSE scores in sham and LLLT groups was 0.13 ± 0.96 and 2.31 ± 1.81 in week 2 (p = 0.00005) and also −0.25 ± 0.86 and 2.53 ± 1.73 in week 8 (p = 0.000003). In the LLLT group, the mean scores of CDR were 1.28 ± 0.71, 1.28 ± 0.71, and 1.25 ± 0.80 at baseline, week 2, and week 8 (p = 0.605 and p = 0.742), respectively. The mean scores of CDR in the sham group were 1.69 ± 0.73, 1.75 ± 0.68, and 1.72 ± 0.82 at baseline, week 2, and week 8, respectively.
Conclusions:
These findings suggest that laser therapy could be a promising treatment modality and an adjunct to pharmacotherapy in dementia patients.
Clinical Trial Registration:
IRCT20191018045148N1 was obtained from the Iranian Registry of Clinical Trials (IRCT.ir).
Get full access to this article
View all access options for this article.
References
1.
BaumgartM, SnyderHM, CarrilloMC, et al.Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. Alzheimer`s Dement, 2015; 11(6):718–722.
2.
Serrano-PozoA, FroschMP, MasliahE, et al.Neuropathological alterations in Alzheimer's disease. Cold Spring Harb Perspect Med, 2011; 1(1):a006189.
3.
HashmiJT, HuangYY, OsmaniBZ, et al.Role of low-level laser therapy in neurorehabilitation. PM R, 2010; 2(12suppl 2):S292–S305.
4.
SchneiderLS, TariotPN, DagermanKS, et al.Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med, 2006; 355(15):1525–1538.
5.
AshrafiF, RezaeiA, AzhidehA, et al.Effectiveness of extremely low-frequency electromagnetic field and pulsed low-level laser therapy in acute stroke treatment. Int Clin Neurosci J, 2020; 7(3):127–131.
6.
Poiani G daCR, ZaninottoAL, CarneiroAMC, et al.Photobiomodulation using low-level laser therapy (LLLT) for patients with chronic traumatic brain injury: A randomized controlled trial study protocol. Trials, 2018; 19(17):1–8.
7.
SaltmarcheAE, NaeserMA, HoKF, et al.Significant improvement in cognition in mild to moderately severe dementia cases treated with transcranial plus intranasal photobiomodulation: Case series report. Photomed Laser Surg, 2017; 35(8):432–441.
8.
HamblinMR. Photobiomodulation for traumatic brain injury and stroke. J Neurosci Res, 2018; 96(4):731–743.
9.
MedradoARAP, PuglieseLS, ReisSRA, et al.Influence of low-level laser therapy on wound healing and its biological action upon myofibroblasts. Lasers Surg Med, 2003; 32(3):239–244.
10.
MesterE, SpiryT, SzendeB, et al.Effect of laser rays on wound healing. Am J Surg, 1971; 122(4):532–535.
11.
MesterE, SzendeB, SpiryT, et al.Stimulation of wound healing by laser rays. Acta Chir Acad Sci Hung, 1973; 14(4):347–356.
12.
RojasJC, Gonzalez-LimaF. Neurological and psychological applications of transcranial lasers and LEDs. Biochem Pharmacol, 2013; 86(4):447–457.
13.
XuZ, GuoX, YangY, et al.Low-level laser irradiation improves depression-like behaviors in mice. Mol Neurobiol, 2017; 54(6):4551–4559.
14.
DisnerSG, BeeversCG, Gonzalez-LimaF. Transcranial laser stimulation as neuroenhancement for attention bias modification in adults with elevated depression symptoms. Brain Stimul, 2016; 9(5):780–787.
15.
LuY, WangR, DongY, et al.Low-level laser therapy for beta-amyloid toxicity in rat hippocampus. Neurobiol Aging, 2017; 49:165–182.
PurushothumanS, NandasenaC, JohnstoneDM, et al.The impact of near-infrared light on dopaminergic cell survival in a transgenic mouse model of parkinsonism. Brain Res, 2013; 1535:61–70.
18.
HennessyM, HamblinMR. Photobiomodulation and the brain: A new paradigm. J Opt, 2017; 19(1):013003.
19.
HendersonTA, MorriesLD. Near-infrared photonic energy penetration: Can infrared phototherapy effectively reach the human brain?. Neuropsychiatr Dis Treat, 2015; 11: 2191–2208.
20.
HamblinMR. Shining light on the head: Photobiomodulation for brain disorders. BBA Clin, 2016; 6:113–124.
21.
XuanW, HuangL, HamblinMR. Repeated transcranial low-level laser therapy for traumatic brain injury in mice: Biphasic dose-response and long-term treatment outcome. J Biophotonics, 2016; 9(11–12):1263–1272.
22.
XuanW, AgrawalT, HuangL, et al.Low-level laser therapy for traumatic brain injury in mice increases brain-derived neurotrophic factor (BDNF) and synaptogenesis. J Biophotonics, 2015; 8(6):502–511.
23.
XuanW, VatanseverF, HuangL, et al.Transcranial low-level laser therapy enhances learning, memory, and neuroprogenitor cells after traumatic brain injury in mice. J Biomed Opt, 2014; 19(10):108003.
24.
OronA, OronU, StreeterJ, et al.Low-level laser therapy applied transcranially to mice following traumatic brain injury significantly reduces long-term neurological deficits. J Neurotrauma, 2007; 24(4):651–656.
25.
Gonzalez-LimaF, BarksdaleBR, RojasJC. Mitochondrial respiration as a target for neuroprotection and cognitive enhancement. Biochem Pharmacol, 2014; 88(4):584–593.
26.
BermanMH, HalperJP, NicholsTW, et al.Photobiomodulation with near-infrared light helmet in a pilot, placebo-controlled clinical trial in dementia patients testing memory and cognition. J Neurol Neurosci, 2017; 8(1):176–182.
27.
ChangJ, RenY, WangR, et al.Transcranial low-level laser therapy for depression and Alzheimer's disease. Neuropsychiatry, 2018; 8(2):477–483.
28.
SyedianM, FallahM, NourozianM, et al.Validity of the Farsi version of Mini-Mental state examination. J Med Council I.R.I, 2008; 25(4):408–414.
29.
SadeghiN, NoroozianM, KhalajiH, et al.Validity and reliability of clinical dementia rating scale among the elderly in Iran. Zahedan J Res Med Sci, 2012; 14:47–50.
30.
BermanMH, NicholsTW. Treatment of neurodegeneration: Integrating photobiomodulation and neurofeedback in Alzheimer's dementia and Parkinson's: A review. Photobiomodul Photomed Laser Surg, 2019; 37(10):623–634.
31.
DantumaNP, BottLC. The ubiquitin-proteasome system in neurodegenerative diseases: Precipitating factor, yet part of the solution. Front Mol Neurosci, 2014; 7(70):1–18.
32.
NicholsTW. Hyperphosphorylation of tau protein in Down's dementia and Alzheimer's disease; methylation and implications in prevention and therapy. J Alzheimers Dis Parkinsonism, 2014; 4(5):1000159.
33.
MyekuN, ClellandCL, EmraniS, et al.Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nat Med, 2016; 22(1):46–53.
34.
KimHP. Lightening up light therapy: Activation of retrograde signaling pathway by photobiomodulation. Biomol Ther, 2014; 22(6):491–496.
35.
GrilloS, DuggettNA, EnnaceurA, et al.Non-invasive infra-red therapy (1072 nm) reduces b-amyloid protein levels in the brain of an Alzheimer's disease mouse model, TASTPM. J Photochem Photobiol B, 2013; 123:13–22.
EliasMF, RalphDD, EliasPK, et al.Neuropsychological test performance, cognitive functioning, blood pressure, and age: The Framingham heart study. Exp Aging Res, 1995; 21(4):369–391.
38.
De Toledo Ferraz AlvesTC, BusattoGF. Regional cerebral blood flow reductions, heart failure, and Alzheimer's disease. Neurol Res, 2006; 28(6):579–587.
39.
De la TorreJC. Treating cognitive impairment with transcranial low-level laser therapy. J Photochem Photobiol B, 2017; 168:149–155.
40.
MaksimovichIV. Endovascular application of low-energy laser in the treatment of dyscirculatory angiopathy of Alzheimer's type. J Behav Brain Sci, 2012; 2(1):67–81.
